7.81
price up icon0.64%   0.05
after-market Handel nachbörslich: 7.80 -0.010 -0.13%
loading
Schlusskurs vom Vortag:
$7.76
Offen:
$7.63
24-Stunden-Volumen:
146.73K
Relative Volume:
0.34
Marktkapitalisierung:
$529.95M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.16M
KGV:
-2.1165
EPS:
-3.69
Netto-Cashflow:
$-134.48M
1W Leistung:
+0.77%
1M Leistung:
-12.83%
6M Leistung:
-38.41%
1J Leistung:
-53.46%
1-Tages-Spanne:
Value
$7.63
$7.88
1-Wochen-Bereich:
Value
$7.255
$8.05
52-Wochen-Spanne:
Value
$6.85
$21.01

Cullinan Therapeutics Inc Stock (CGEM) Company Profile

Name
Firmenname
Cullinan Therapeutics Inc
Name
Telefon
617-410-4650
Name
Adresse
ONE MAIN STREET, CAMBRIDGE
Name
Mitarbeiter
111
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CGEM's Discussions on Twitter

Vergleichen Sie CGEM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CGEM
Cullinan Therapeutics Inc
7.81 529.95M 0 -153.16M -134.48M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-11 Fortgesetzt Stifel Buy
2024-10-24 Eingeleitet UBS Buy
2024-05-01 Eingeleitet Stifel Buy
2024-04-15 Eingeleitet William Blair Outperform
2024-02-15 Eingeleitet Wedbush Outperform
2023-06-15 Eingeleitet TD Cowen Outperform
2022-11-21 Eingeleitet BTIG Research Buy
2021-04-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-02-02 Eingeleitet Evercore ISI Outperform
2021-02-02 Eingeleitet Morgan Stanley Equal-Weight
2021-02-02 Eingeleitet SVB Leerink Outperform
2021-02-01 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten

pulisher
Jun 17, 2025

Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech

Jun 17, 2025
pulisher
Jun 17, 2025

Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World

Jun 17, 2025
pulisher
Jun 12, 2025

Cullinan Management Holds Annual Stockholders Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech

Jun 12, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix - MENAFN.com

Jun 05, 2025
pulisher
Jun 05, 2025

Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Cullinan Therapeutics, Inc.Special Call - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan (CGEM) Secures Global Rights for Velinotamig from Genri - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velin - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan expands autoimmune focus with new T cell engager license - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics (CGEM) Secures Exclusive License for Velinotamig Development | CGEM Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Management Enters Global License Agreement with Genrix - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan in pact for multiple myeloma drug (CGEM:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific ... - Eagle-Tribune

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Cuts Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by Nuveen Asset Management LLC - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Decline in Short Interest - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILI - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Cullinan Therapeutics IncTaiho Oncology And Cullinan Therapeutics Publish Positive Rezilient1 Trial Results - MarketScreener

Jun 01, 2025
pulisher
Jun 01, 2025

Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire

Jun 01, 2025
pulisher
Jun 01, 2025

ProShare Advisors LLC Acquires 4,124 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

Jun 01, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference | CGEM Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - Yahoo Finance

May 29, 2025
pulisher
May 26, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Sold by D. E. Shaw & Co. Inc. - Defense World

May 26, 2025
pulisher
May 24, 2025

Ameriprise Financial Inc. Raises Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 24, 2025
pulisher
May 22, 2025

Cullinan Therapeutics (CGEM) Reveals Promising Phase 2b Results - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology Announce Positive Results from REZILIENT1 Trial of Zipalertinib in Advanced Lung Cancer Patients - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewswire

May 22, 2025
pulisher
May 21, 2025

Northern Trust Corp Raises Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World

May 21, 2025
pulisher
May 20, 2025

115,000 Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Acquired by BNP Paribas Financial Markets - Defense World

May 20, 2025
pulisher
May 15, 2025

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World

May 15, 2025
pulisher
May 14, 2025

Cullinan Therapeutics (CGEM) Projected to Announce Quarterly Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 13, 2025

Cullinan Therapeutics (CGEM): UBS Lowers Price Target but Mainta - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Cullinan Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025

Finanzdaten der Cullinan Therapeutics Inc-Aktie (CGEM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cullinan Therapeutics Inc-Aktie (CGEM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
AHMED NADIM
President and CEO
Feb 25 '25
Sale
8.53
12,529
106,872
430,621
Michaelson Jennifer
Chief Scientific Officer
Feb 25 '25
Sale
8.53
3,756
32,039
142,004
SUMER JACQUELYN L
Chief Legal Officer
Feb 25 '25
Sale
8.53
3,756
32,039
136,895
Michaelson Jennifer
Chief Scientific Officer
Jan 06 '25
Sale
12.51
4,000
50,040
95,760
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
Kapitalisierung:     |  Volumen (24h):